Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Margaret H. Reynolds"'
Autor:
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila, Mark T. A. Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao, Margaret H. Reynolds, Sarah M. Phillips, Tara Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
How different oncogenic Akt mutants can affect the response to Akt inhibitors is currently unclear. Here, the authors analyse somatic mutations of Akt1-3 isoforms in several human cancers, investigate their oncogenic effects and therapeutic relevance
Externí odkaz:
https://doaj.org/article/2f4ee7e6727f4b59871619d4a10453d0
Autor:
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila, Mark T. A. Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao, Margaret H. Reynolds, Sarah M. Phillips, Tara Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor
Publikováno v:
Nature communications. 13(1)
AKT- a key molecular regulator of PI-3K signaling pathway, is somatically mutated in diverse solid cancer types, and aberrant AKT activation promotes altered cancer cell growth, survival, and metabolism1–8. The most common of AKT mutations (AKT1 E1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da0a56f19f0f58462da34de7cd8c41c
https://pubmed.ncbi.nlm.nih.gov/35440569
https://pubmed.ncbi.nlm.nih.gov/35440569